biote Corp. Class A BTMD 深 沪
等待开盘 08-19 09:30:00 美东时间
1.317
-0.053
-3.87%
华盛通- 最 高1.40
- 今 开1.40
- 成交量 17.31万股
- 最 低 1.31
- 昨 收 1.37
- 总市值 4731.65万
- 52周最高 3.62
- 市盈率 静 1.79
- 换手率 0.48%
- 52周最低 1.27
- 委 比 77.97%
- 总股本 3592.75万
- 历史最高 12.08
- 量 比 1.38
- 振 幅 6.57%
- 历史最低 1.27
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
TD Cowen Maintains Buy on Biote, Lowers Price Target to $2
TD Cowen analyst Jonna Kim maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $2.5 to $2.
08-08 05:16
Biote Q2 EPS $(0.23) Misses $0.04 Estimate, Sales $44.232M Miss $46.148M Estimate
Biote (NASDAQ:BTMD) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $0.04 by 675 percent. This is a 330 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $44.232 million which missed...
08-06 04:08
Biote Reaffirms FY26 Guidance For Revenue Above $190M And Adjusted EBITDA Above $38M
Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year.
05-28 21:12
Biote Appoints CFO And Chief Business Officer Bob Peterson As Interim CEO And Director, Effective June 8; Bret Christensen Steps Down As CEO
Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and
05-28 21:11
ImmunityBio acquiring U.S. rights to Tokyo strain of BCG
ImmunityBio (IBRX) on Saturday announced a licensing deal to acquire exclusive U.S. rights to a bladder cancer therapy called Bacillus Calmette-Guerin (BCG) treatment from Japan BCG Laboratory, a Japa...
05-17 02:11
Why Is HCW Biologics Stock Gaining Today?
HCW Biologics shares soared Friday after the company reported stronger quarterly results, advanced a key licensing deal and reaffirmed upcoming autoimmune clinical data milestones despite ongoing going-concern risks.
05-16 01:35
Full Transcript: Arrive AI Q1 2026 Earnings Call
Arrive AI (NASDAQ:ARAI) released first-quarter financial results and hosted an ...
05-15 21:29
Precipio Announces Q1 2026 Financial Results
Precipio, Inc. reported first-quarter 2026 revenue of $6.71M, flat from Q4-2025 but up 36% year-over-year. Product revenue declined temporarily due to delayed shipments. Adjusted EBITDA was $(0.16)M, impacted by CMS cuts, product shipment delays, and hiring costs. Cash flow was positive $60K. CEO Ilan Danieli noted underlying growth, particularly in the expanding product pipeline, expecting second-half growth.
05-14 21:00
